This article explores SEND datasets and FDA nonclinical submission standards, addressing critical compliance challenges in pharmaceutical development. IntuitionLabs, founded by industry veteran Adrien Laurent with over two decades of enterprise software expertise, offers custom AI solutions tailored for life sciences companies navigating these complex regulatory requirements. The document provides educational guidance on standardizing nonclinical data submissions while emphasizing that readers should independently verify information and consult qualified professionals for specific regulatory and legal matters. IntuitionLabs specializes in leveraging artificial intelligence to streamline data integration and compliance processes for pharmaceutical organizations.

The FDA's 2026 cybersecurity updates represent a fundamental transition from voluntary guidelines to mandatory requirements for connected medical devices. Effective February 2, 2026, cybersecurity becomes integrated into the Quality Management System Regulation, embedding security directly into product quality standards rather than treating it as a separate function. Under Section 524B of the FD&C Act, manufacturers must now adopt a Secure Product Development Framework, implementing security measures throughout the entire device lifecycle from design to decommissioning. Non-compliance constitutes a prohibited act with potential regulatory penalties and operational disruptions. Manufacturers must align with recognized standards such as IEC 81001-5-1 and document all cybersecurity efforts within the Design History File for FDA review. This enforcement shift reflects the regulatory body's commitment to enhancing patient safety and data integrity in connected medical devices.

The framework is intended primarily for manufacturers of AI-enabled medical devices, including those incorporating machine learning, and recognizes that devices ...

The FDA has released updated cybersecurity guidance for medical device manufacturers, superseding its previous 2025 guidance. While non-binding, the guidance emphasizes that cybersecurity risk management is critical to ensuring devices remain safe and effective. Medical devices remain prime targets for cyber criminals, making robust security practices essential. The guidance supplements existing premarket and postmarket cybersecurity directives and aligns with broader federal cybersecurity initiatives, including the White House's Cyber Strategy for America. Rather than mandating specific technical measures, the FDA recommends manufacturers assess various cybersecurity controls during premarket submissions, such as secure design and architecture, while incorporating the ISO 13485 risk management framework. Companies should review their practices to meet FDA expectations and fulfill statutory obligations.

IntuitionLabs addresses critical challenges in AI post-market surveillance for the pharmaceutical and life sciences industries. Founded in 2023 by Adrien Laurent, the company specializes in custom AI solutions drawing on 25+ years of enterprise software expertise. This educational resource explores the distinction between locked and continuous learning approaches in AI monitoring systems, relevant to evolving FDA regulatory frameworks. The document emphasizes that readers should independently verify critical information and consult qualified professionals for specific business guidance, as AI-generated content may contain errors or omissions requiring careful review.

The FDA is increasingly requiring AI and machine learning-based medical devices to demonstrate explainability alongside strong performance metrics. While manufacturers have traditionally focused on developing sophisticated algorithms with high validation accuracy, regulatory reviewers now demand comprehensive documentation of how these models function, their limitations, and their clinical implications. The agency recognizes that clinicians must understand and potentially intervene in AI-generated diagnoses or treatment recommendations, rather than accepting black-box outputs regardless of accuracy. This shift reflects the FDA's commitment to ensuring patient safety by enabling informed clinical decision-making. Manufacturers submitting 510(k) and De Novo applications must therefore prioritize transparency and interpretability, addressing deficiency letters that challenge algorithmic opacity and substantiating clinician trust in these medical devices.

The FDA faces significant challenges regulating adaptive artificial intelligence medical devices as technology rapidly evolves beyond existing regulatory frameworks. With approximately 1,450 AI-enabled medical devices already authorized and generative AI entering clinical settings, the agency's statutory authority—designed for static hardware—proves inadequate for software that learns and adapts post-deployment. Most devices were cleared via the 510(k) pathway, concentrated in radiology, cardiology, and neurology. The fundamental challenge is that machine learning algorithms can materially change after market approval through continuous updates, unlike traditional devices with fixed functionality. The Government Accountability Office has formally recommended the FDA identify necessary statutory changes and communicate them to Congress, underscoring the regulatory framework's unsettled status and high-stakes implications for patient safety.

The FDA has issued draft guidance on artificial intelligence applications in drug development, addressing critical regulatory considerations for pharmaceutical companies. IntuitionLabs, founded by industry veteran Adrien Laurent with over two decades of enterprise software expertise, offers customized AI solutions tailored to life sciences organizations navigating these evolving regulations. The guidance encompasses standards such as ICH M8 eCTD v4.0 submissions, helping companies understand AI implementation requirements throughout the drug development lifecycle. As AI adoption accelerates in pharmaceutical research, this framework provides essential clarity for organizations seeking to integrate machine learning and artificial intelligence technologies while maintaining regulatory compliance and data integrity throughout their development processes.

The FDA has relied on CDISC's Study Data Tabulation Model (SDTM) as the mandatory standard for organizing clinical trial data submissions since 2004. However, this foundational infrastructure is undergoing its most significant overhaul in two decades as modern drug development has become exponentially more complex. Contemporary trials now incorporate decentralized studies, adaptive designs, cell and gene therapies, and real-world evidence—challenges the SDTM framework was not designed to address. Current limitations became apparent in complex oncology trials featuring rescreening and re-enrollment protocols, where the existing data structure struggled to accommodate multiple participant iterations within a single trial. This modernization effort reflects the critical need to update data standardization practices to support evolving clinical research methodologies and ensure continued FDA regulatory efficiency.

Healthcare cybersecurity has evolved from a purely technical IT function to a critical operational and patient safety concern. Modern healthcare organizations depend heavily on interconnected digital infrastructure, including electronic health records, medical devices, and scheduling systems. When cyberattacks occur, they cascade across these integrated systems, disrupting clinical workflows, delaying procedures, and forcing organizations to revert to manual processes that increase error risk. Recent ransomware incidents demonstrate that cybersecurity threats now directly impact care delivery, financial stability, and regulatory compliance. Healthcare institutions must recognize cyber risk as an operational risk requiring coordination across clinical, compliance, and operational leadership rather than treating it as an isolated IT responsibility.

Infusion providers are increasingly deploying artificial intelligence tools for prior authorization, clinical documentation, revenue cycle management, and patient scheduling. However, many organizations lack adequate legal and compliance frameworks to manage the substantial regulatory and liability risks these technologies introduce. Without proper governance structures, infusion providers face exposure under HIPAA, the False Claims Act, and emerging state AI regulations. Misclassification or misuse of AI in clinical decision-making or billing workflows can create significant compliance gaps affecting operations and transaction value. For providers considering strategic transactions, AI governance is now a critical due diligence consideration. Best practices include conducting a comprehensive AI tool inventory, ensuring HIPAA-compliant vendor agreements, implementing human oversight in billing applications, and establishing formal written AI governance policies to address evolving regulatory requirements.

Researchers from Peking University and the California Institute of Technology have developed a breakthrough bioelectronic interface called SIRES (Strain-Resilient Intrinsically Stretchable Electrochemical biointerface). This innovative platform addresses a critical challenge in soft bioelectronics by enabling molecular sensors to maintain accurate readings while attached to moving biological tissues that stretch and deform. The technology maintains high-fidelity electrochemical outputs under tensile strains up to 300% and supports multiple sensing modes including voltammetric, amperometric, and potentiometric detection. Led by Prof. Yadong Xu and Professor Wei Gao, the research demonstrates applications in both wearable and implantable formats, including sweat monitoring, opening new possibilities for continuous health monitoring and molecular signal tracking on dynamic tissues.

Generative AI is revolutionizing healthcare through diverse applications that enhance clinical efficiency and patient outcomes. This comprehensive resource explores seventeen distinct use cases where AI technologies are being deployed across the healthcare sector. The applications span diagnostic assistance, treatment optimization, administrative automation, and clinical decision support. By leveraging large language models and advanced AI frameworks, healthcare organizations can streamline workflows, reduce operational costs, and improve care quality. These use cases demonstrate AI's transformative potential in addressing critical healthcare challenges, from personalized medicine to data management. The integration of generative AI in healthcare represents a significant advancement in modern medical practice, offering practitioners and administrators powerful tools to enhance service delivery while maintaining security and compliance standards.

The FDA has updated its guidance on real-world evidence, removing a significant barrier by allowing medical device sponsors to submit de-identified data in regulatory submissions. Previously, the agency required individually identifiable patient-level data, which restricted access to large-scale de-identified datasets from electronic health records, insurance claims, and disease registries. This December 2025 policy shift signals the FDA's growing willingness to engage with practical realities of modern clinical evidence generation. The change is expected to facilitate broader adoption of real-world evidence across medical devices and potentially influence how drug and biologic developers approach evidence collection and submission strategies.

Glucotrack’s Continuous Blood Glucose Monitor (CBGM) is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use.

The FDA's Digital Health Center of Excellence has released comprehensive guidance documents addressing the regulation of digital health products and medical device software. These guidances cover critical topics including clinical decision support software, artificial intelligence-enabled device functions, cybersecurity considerations, and remote data acquisition technologies. Recent updates emphasize lifecycle management for AI-enabled software, predetermined change control plans, and quality system integration. The guidance documents establish regulatory frameworks for device software functions, mobile medical applications, and off-the-shelf software implementation. These resources provide essential clarity on premarket submission requirements, interoperability standards, and compliance pathways for manufacturers developing digital health innovations. The FDA continues updating these guidances to address emerging technologies and evolving regulatory considerations in the digital health landscape.

The Centers for Medicare & Medicaid Services has issued guidance enabling remote patient monitoring (RPM) as part of its COVID-19 pandemic response. RPM allows clinicians to remotely track vital signs including temperature, blood pressure, and oxygen saturation using digitally connected, non-invasive devices such as pulse oximeters and home blood pressure monitors. This technology enables COVID-19 patients to safely recover at home while maintaining continuous clinical oversight, particularly important for monitoring oxygen levels and detecting pneumonia onset. Originally developed for chronic disease management, RPM utilizes specific Current Procedure Terminology codes to facilitate reimbursement. The approach provides objective physiological data, enabling more precise clinical decision-making than subjective symptom reporting alone.

HIPAA's Security Rule is undergoing its most significant overhaul in over a decade, driven by escalating ransomware attacks, credential-based intrusions, and the proliferation of cloud computing, artificial intelligence, and telehealth technologies. With 725 breaches affecting over 275 million records in 2024, regulators are fundamentally reshaping compliance requirements. The updated framework shifts from flexible, "addressable" safeguards to mandatory, enforceable technical controls. Organizations can no longer exercise discretion in determining which safeguards apply to their environment. The proposed rule, introduced in January 2025, is expected to finalize in May 2026, with a compliance window of approximately 180 days thereafter. This prescriptive approach aligns HIPAA with contemporary cybersecurity practices and demands substantive implementation and testing rather than policy documentation alone.

EY addresses the critical gap in digital healthcare infrastructure for rural communities by developing a minimum viable digital foundation tailored to resource-constrained environments. This approach leverages data and technology to enable rural health providers to deliver quality care while building sustainable, scalable systems. By combining EY's expertise in technology transformation, operations, and strategic consulting, the initiative helps rural healthcare organizations establish essential digital capabilities that support long-term value creation. The framework prioritizes trust, accessibility, and practical implementation, enabling rural health systems to transform operations and improve patient outcomes despite limited resources and infrastructure challenges.

L’essor de l’intelligence artificielle, du Big Data, de la blockchain et de la télémédecine ouvre de nouvelles perspectives pour une médecine plus personnalisée, efficace et accessible. La digitalisation n’est plus une option mais une nécessité stratégique pour améliorer l’efficacité des soins.